ALMIB Stock Overview
Develops biological biocides for the prevention of microbiological risk for water, crop protection and health sectors. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Amoéba S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €0.79 |
| 52 Week High | €0.86 |
| 52 Week Low | €0.36 |
| Beta | -0.064 |
| 11 Month Change | 51.15% |
| 3 Month Change | 36.22% |
| 1 Year Change | 96.75% |
| 33 Year Change | -30.44% |
| 5 Year Change | 78.84% |
| Change since IPO | -91.26% |
Recent News & Updates
Shareholder Returns
| ALMIB | FR Chemicals | FR Market | |
|---|---|---|---|
| 7D | 21.1% | -1.8% | -0.3% |
| 1Y | 96.7% | -0.6% | -3.5% |
Return vs Industry: ALMIB exceeded the French Chemicals industry which returned 0.8% over the past year.
Return vs Market: ALMIB exceeded the French Market which returned -2.5% over the past year.
Price Volatility
| ALMIB volatility | |
|---|---|
| ALMIB Average Weekly Movement | 7.4% |
| Chemicals Industry Average Movement | 5.4% |
| Market Average Movement | 4.5% |
| 10% most volatile stocks in FR Market | 9.2% |
| 10% least volatile stocks in FR Market | 2.2% |
Stable Share Price: ALMIB's share price has been volatile over the past 3 months compared to the French market.
Volatility Over Time: ALMIB's weekly volatility (7%) has been stable over the past year, but is still higher than 75% of French stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 22 | Jean-Francois Doucet | amoeba-nature.com |
Amoéba S.A. develops biological biocides for the prevention of microbiological risk for water, crop protection and health sectors. It develops applications using amoeba Willaertia magna C2c Maky. The company was incorporated in 2010 and is based in Chassieu, France.
Amoéba S.A. Fundamentals Summary
| ALMIB fundamental statistics | |
|---|---|
| Market cap | €39.00m |
| Earnings (TTM) | -€13.42m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.9x
P/E RatioIs ALMIB overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ALMIB income statement (TTM) | |
|---|---|
| Revenue | €0 |
| Cost of Revenue | €1.28m |
| Gross Profit | -€1.28m |
| Other Expenses | €12.15m |
| Earnings | -€13.42m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.27 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -122.1% |
How did ALMIB perform over the long term?
See historical performance and comparison